Maribavir

Summary

Maribavir (CHEMBL515408) is an approved small molecule (ATC J05AX10); indicated across 2 conditions including viral infectious disease and cytomegalovirus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AX10
• Indications: 2 conditions
• Clinical trials: 20
• Chemistry: 376.2 Da · C15H19Cl2N3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL515408
Name	Maribavir
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	471161
ATC	J05AX10
Molecular formula	C15H19Cl2N3O4
Molecular weight	376.2
InChIKey	KJFBVJALEQWJBS-XUXIUFHCSA-N

SMILES: CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl

IUPAC name: (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol

Also known as: 1263W94, BW-1263W94, GW-257406X, Livtencity, Maribavir, maribavir, MARIBAVIR, C0088787

Patent coverage: 253 distinct patent families (958 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 940 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Protein deacetylase HDAC6.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HDAC6	6.17	IC50	669	nM	CHEMBL_ACT_23141020

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
cytomegalovirus infection	4	MONDO:0005132	EFO:0001062

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE3	8
PHASE1	5
PHASE2	3
Not specified	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06034925	PHASE4	COMPLETED	Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
NCT05319353	PHASE3	RECRUITING	A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT06439342	PHASE3	RECRUITING	A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT07511127	PHASE3	RECRUITING	Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
NCT00411645	PHASE3	COMPLETED	Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
NCT00497796	PHASE3	COMPLETED	Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
NCT02927067	PHASE3	COMPLETED	A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
NCT02931539	PHASE3	COMPLETED	Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
NCT05137717	PHASE3	COMPLETED	A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
NCT07014319	PHASE2	RECRUITING	Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies
NCT00223925	PHASE2	COMPLETED	Maribavir for Prevention of CMV After Stem Cell Transplants
NCT01611974	PHASE2	COMPLETED	Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
NCT00002373	PHASE1	COMPLETED	The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
NCT02775240	PHASE1	COMPLETED	Study of SHP620 (Maribavir) in Healthy Adults
NCT04131556	PHASE1	TERMINATED	A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
NCT04497883	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants
NCT05382104	PHASE1	COMPLETED	Maribavir Food-Effect Study in Healthy Adults Participants
NCT06555432	Not specified	RECRUITING	A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
NCT06577363	Not specified	RECRUITING	A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
NCT07141095	Not specified	NOT_YET_RECRUITING	A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).